What is Cold Laser Therapy?

History Cold Laser Therapy (“CLT”) or treatment with light has been in existence since 1500 BC; where, Indian medical literature described a treatment combining herbs with natural sunlight to treat non-pigmented skin areas, known today as vitiligo. Buddhist literature from 200 AD and 10th century Chinese documents make similar references.1 As an analogy, just like the abacus eventually evolved into the computer, which has fundamentally changed the way humans live and work in today’s society (put up your hand if you can go a day without your smartphone), light therapy, using research from 3500 years ago, has evolved into CLT systems capable of delivering laser light at specific wavelengths (colours) and power levels to heal numerous nerve, muscle and joint conditions. Benefits As advancements in CLT technology have continued, millions of healthcare practitioners now rely on CLT systems daily in their clinics to treat a wide variety of conditions by: … Read More

Developing a Potential Cure for Bladder Cancer

Current bladder cancer treatments are not curative. A novel photodynamic therapy (PDT) platform being developed by Theralase could be the new gold standard.  Limited Options for Bladder Cancer Patients Bladder cancer is the ninth most common cancer globally.1 Approximately 75–85% of patients with bladder cancer present with non-muscle invasive bladder cancer (NMIBC). Adjuvant intravesical instillations with bacillus Calmette-Guérin (BCG) is the recommended treatment option for patients with intermediate- and high-risk NMIBC. Despite adequate BCG treatment, a large proportion of patients experience a recurrence. Although radical cystectomy is the gold standard for BCG-unresponsive NMIBC, some patients are unfit or unwilling to consider this option. BCG also has known side effects that impact patient acceptance and there has been a worldwide supply shortage since 2012. Despite bladder cancer being the fifth most common cancer in the United States, there have been virtually no advances in its treatment. Currently, intravesical therapies are limited by … Read More

Theralase – Participating in Bladder Cancer Walk 2019

Theralase® is proud to support the Bladder Cancer Canada annual awareness walk. Bladder Cancer Canada is the first and only Canadian patient advocacy organization dedicated to bladder cancer issues. Bladder cancer is the fifth most common cancer worldwide and approximately 241,000 new cases of bladder cancer will be diagnosed in Canada, the United States and Europe this year 1. Theralase’s lead cancer indication, currently being evaluated in a Phase II clinical study is Bacillus Calmete Guérin (“BCG”)-Unresponsive Carcinoma In-Situ (“CIS”) Non-Muscle Invasive Bladder Cancer (“NMIBC”). These PhotoDynamic Compounds (“PDC”) are able to hunt and penetrate preferentially into cancer cells, leaving healthy cells intact, and when laser light activated destroy the cancer cells safely and effectively with minimum to no side effects. If this pivotal study is proven successful, it will lead to a safe and effective treatment option for patients presenting with devastating disease. When a patient hears the word … Read More

Canadian Clinical Stage Biopharmaceutical Company Advances New Cancer Treatment

A Toronto based clinical-stage biopharmaceutical company is quickly advancing on what may prove to be one of the safest and most effective cancer treatments ever developed. Theralase Technologies Inc. (“Theralase”) is conducting a pivotal Phase II clinical study, with a primary objective of efficacy, of a cutting-edge anti-cancer treatment that utilizes laser light activated anti-cancer drugs; known as Photo Dynamic Compounds (“PDCs”), to destroy cancer cells from the inside out. In other words, these PDCs are able to penetrate preferentially into cancer cells, leaving healthy cells intact, and when laser light activated destroy the cancer cells safely and effectively with minimum to no side effects. Theralase is currently investigating these PDCs in the destruction of Non-Muscle Invasive Bladder Cancer (“NMIBC”) via a pivotal Phase II clinical study. Founded in 1994,Theralase commenced the research, development and commercialization of therapeutic lasers for the elimination of knee pain and continues this business today; … Read More

Active Rehabilitation – How Much is Too Much?

With temperatures starting to rise again, more and more people are out enjoying the weather and being active. With this increase in activity, there always seems to be an increase in injuries.